On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives
- PMID: 23905670
- PMCID: PMC3978625
- DOI: 10.1186/bcr3437
On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives
Abstract
The increasing importance of signal transducer and activator of transcription 3 (STAT3) expression in human cancers has led several laboratories to examine in detail the expression of one of its major negative regulators in oncogenesis--the T-cell protein tyrosine phosphatase, nonreceptor type 2 (PTPN2). A recent paper by Shields and colleagues points to the associate depletion of PTPN2 in STAT3-positive breast cancers. We examine these findings and reflect on the mechanism of action of PTPN2 and the consequences of its modulation for STAT3 downstream signaling.
Comment on
-
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.Mol Cell Biol. 2013 Feb;33(3):557-70. doi: 10.1128/MCB.01016-12. Epub 2012 Nov 19. Mol Cell Biol. 2013. PMID: 23166300 Free PMC article.
References
-
- Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamburger T, Maly B, Allweis TM, Peretz T. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2013;15:407–413. doi: 10.1007/s10549-013-2453-x. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
